SABS | tickerfilter.com

Fundamental analysis

37%

Profitability 36%

Dept financing 24%

Liquidity 58%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.81%

1 Month

-7.85%

3 Months

-14.77%

6 Months

16.17%

1 Year

101.14%

2 Year

-12.22%

Key data

Stock price

$3.52

P/E Ratio

N/A

DAY RANGE

$3.51 - $3.75

EPS

-$1.72

52 WEEK RANGE

$1.53 - $6.60

52 WEEK CHANGE

$96.66

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

50.951 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-19-2025

BETA

-0.16

PUBLIC FLOAT

AVERAGE 10 VOLUME

$459,021

AVERAGE 30 VOLUME

$453,233

Company detail

CEO: Eddie J. Sullivan
Region: US
Website: sabbiotherapeutics.com
Employees: 140
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

SABS - SAB Biotherapeutics, Inc.